EA020257B1 - НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ - Google Patents

НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ Download PDF

Info

Publication number: EA020257B1
Authority: EA; Eurasian Patent Office
Prior art keywords: ifn; peg; conjugate; formula; kda
Prior art date: 2010-07-20

Application number

EA201100809A

Other languages

English (en)

Russian (ru)

Other versions

EA201100809A1 (ru

Inventor

Татьяна Вениаминовна ЧЕРНОВСКАЯ

Лев Александрович Денисов

Дмитрий Валентинович МОРОЗОВ

Елена Георгиевна Руденко

Ангелина Всеволодовна Кленова

Original Assignee

Закрытое Акционерное Общество "Биокад"

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-20

Filing date

2011-06-21

Publication date

2014-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA020257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-21 Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"

2012-01-30 Publication of EA201100809A1 publication Critical patent/EA201100809A1/ru

2014-09-30 Publication of EA020257B1 publication Critical patent/EA020257B1/ru

Links

229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 70
108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 12
102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 12
239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 4
238000002360 preparation method Methods 0.000 title description 11
230000001900 immune effect Effects 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 30
229940079593 drug Drugs 0.000 claims abstract description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
238000011282 treatment Methods 0.000 claims abstract description 17
201000010099 disease Diseases 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 9
201000011510 cancer Diseases 0.000 claims abstract description 8
208000031951 Primary immunodeficiency Diseases 0.000 claims abstract description 4
206010054979 Secondary immunodeficiency Diseases 0.000 claims abstract description 4
239000000178 monomer Substances 0.000 claims abstract description 4
230000000840 anti-viral effect Effects 0.000 claims description 26
238000000034 method Methods 0.000 claims description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
230000003612 virological effect Effects 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
235000002639 sodium chloride Nutrition 0.000 claims description 10
208000005176 Hepatitis C Diseases 0.000 claims description 9
239000000872 buffer Substances 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 9
230000002265 prevention Effects 0.000 claims description 7
208000002672 hepatitis B Diseases 0.000 claims description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
229920000053 polysorbate 80 Polymers 0.000 claims description 6
235000017281 sodium acetate Nutrition 0.000 claims description 6
230000001028 anti-proliverative effect Effects 0.000 claims description 5
230000002519 immonomodulatory effect Effects 0.000 claims description 5
230000000771 oncological effect Effects 0.000 claims description 5
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
235000011054 acetic acid Nutrition 0.000 claims description 4
235000018417 cysteine Nutrition 0.000 claims description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
201000001441 melanoma Diseases 0.000 claims description 4
229940068968 polysorbate 80 Drugs 0.000 claims description 4
239000008215 water for injection Substances 0.000 claims description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
208000025113 myeloid leukemia Diseases 0.000 claims description 3
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
229960000329 ribavirin Drugs 0.000 claims description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
229940087562 sodium acetate trihydrate Drugs 0.000 claims description 2
239000003381 stabilizer Substances 0.000 claims description 2
229960000583 acetic acid Drugs 0.000 claims 1
229940090047 auto-injector Drugs 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940071643 prefilled syringe Drugs 0.000 claims 1
229960002668 sodium chloride Drugs 0.000 claims 1
108010050904 Interferons Proteins 0.000 abstract description 60
102000014150 Interferons Human genes 0.000 abstract description 60
230000000694 effects Effects 0.000 abstract description 29
108090000765 processed proteins & peptides Proteins 0.000 abstract description 15
229940079322 interferon Drugs 0.000 abstract description 12
102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract description 7
239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
208000036142 Viral infection Diseases 0.000 abstract description 2
229920001184 polypeptide Polymers 0.000 abstract description 2
230000009385 viral infection Effects 0.000 abstract description 2
229940047124 interferons Drugs 0.000 description 50
108090000623 proteins and genes Proteins 0.000 description 31
235000018102 proteins Nutrition 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 30
125000003277 amino group Chemical group 0.000 description 15
239000000243 solution Substances 0.000 description 14
238000001962 electrophoresis Methods 0.000 description 13
-1 trasylate Chemical compound 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
238000001819 mass spectrum Methods 0.000 description 12
239000002158 endotoxin Substances 0.000 description 9
230000006320 pegylation Effects 0.000 description 9
230000005847 immunogenicity Effects 0.000 description 8
239000002594 sorbent Substances 0.000 description 8
238000004007 reversed phase HPLC Methods 0.000 description 7
239000007974 sodium acetate buffer Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
235000018977 lysine Nutrition 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108010092851 peginterferon alfa-2b Proteins 0.000 description 6
229940106366 pegintron Drugs 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
102000004142 Trypsin Human genes 0.000 description 5
108090000631 Trypsin Proteins 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
238000005341 cation exchange Methods 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 5
229940043264 dodecyl sulfate Drugs 0.000 description 5
125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000012588 trypsin Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
108091006006 PEGylated Proteins Proteins 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
230000006872 improvement Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229920001427 mPEG Polymers 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000001632 sodium acetate Substances 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 3
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical class CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000011521 glass Substances 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
229940126601 medicinal product Drugs 0.000 description 3
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000002797 proteolythic effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010008909 Chronic Hepatitis Diseases 0.000 description 2
208000006154 Chronic hepatitis C Diseases 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
229920005549 butyl rubber Polymers 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
208000010710 hepatitis C virus infection Diseases 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
238000012454 limulus amebocyte lysate test Methods 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000011146 sterile filtration Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
150000003918 triazines Chemical class 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 1
FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
JDXQWYKOKYUQDN-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione Chemical class OC1CC(=O)NC1=O JDXQWYKOKYUQDN-UHFFFAOYSA-N 0.000 description 1
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
229920005682 EO-PO block copolymer Polymers 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
239000012480 LAL reagent Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
206010023849 Laryngeal papilloma Diseases 0.000 description 1
241000283986 Lepus Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
101100222379 Rattus norvegicus Cxcl10 gene Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
241000566576 Tyto Species 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
MKHVZQXYWACUQC-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;dodecyl sulfate Chemical compound OCCNCCO.CCCCCCCCCCCCOS(O)(=O)=O MKHVZQXYWACUQC-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000249 desinfective effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical class CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000004090 etiopathogenesis Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
229920001973 fluoroelastomer Polymers 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000009000 laryngeal papillomatosis Diseases 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000002483 medication Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical class CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940093625 propylene glycol monostearate Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
FDRPZJWMPZUHBN-UHFFFAOYSA-N triazin-2-ium;chloride Chemical class Cl.C1=CN=NN=C1 FDRPZJWMPZUHBN-UHFFFAOYSA-N 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009265 virologic response Effects 0.000 description 1
CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Oncology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EA201100809A 2010-07-20 2011-06-21 НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ EA020257B1 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU2010129824/10A RU2447083C1 (ru)	2010-07-20	2010-07-20	НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Publications (2)

Publication Number	Publication Date
EA201100809A1 EA201100809A1 (ru)	2012-01-30
EA020257B1 true EA020257B1 (ru)	2014-09-30

Family

ID=45497062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA201100809A EA020257B1 (ru)	2010-07-20	2011-06-21	НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Country Status (20)

Country	Link
KR (1)	KR101586372B1 (es)
CN (1)	CN102617736B (es)
AR (1)	AR087227A1 (es)
BR (1)	BRPI1101565A2 (es)
CO (1)	CO6680611A2 (es)
CR (1)	CR20130021A (es)
CU (1)	CU24193B1 (es)
DO (1)	DOP2013000002A (es)
EA (1)	EA020257B1 (es)
EC (1)	ECSP13012398A (es)
MX (1)	MX2011007458A (es)
MY (1)	MY168784A (es)
NI (1)	NI201300008A (es)
PE (1)	PE20131034A1 (es)
PH (1)	PH12012502425A1 (es)
RU (1)	RU2447083C1 (es)
SG (1)	SG187117A1 (es)
UA (1)	UA99766C2 (es)
UY (1)	UY33525A (es)
WO (1)	WO2012011836A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2515913C1 (ru) *	2013-03-22	2014-05-20	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика")	ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ)
EA021610B1 (ru) *	2013-03-28	2015-07-30	Илья Александрович МАРКОВ	Жидкое противовирусное лекарственное средство
EA021643B1 (ru) *	2013-03-28	2015-07-30	Илья Александрович МАРКОВ	Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
CN103463623B (zh) *	2013-09-03	2015-09-09	长春海伯尔生物技术有限责任公司	一种聚乙二醇干扰素注射液及其制备方法
RU2554761C1 (ru) *	2014-05-13	2015-06-27	Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии"	Противоэнтеровирусное и иммуностимулирующее средство
RU2572800C1 (ru) *	2014-09-22	2016-01-20	Закрытое Акционерное Общество "Биокад"	Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
EA029498B1 (ru) *	2015-11-24	2018-04-30	Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ)	ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ
RU2678332C1 (ru)	2017-09-08	2019-01-28	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ")	Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
AU2021258734A1 (en) *	2020-04-20	2023-01-05	Altum Pharmaceuticals Inc.	Recombinant interferon
CN114392237B (zh) *	2021-12-28	2024-02-02	上海允英生物医药科技有限公司	一种冻干病毒制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5951974A (en) *	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
WO2004022630A2 (en) *	2002-09-09	2004-03-18	Nektar Therapeutics Al, Corporation	Water-soluble polymer alkanals

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030053982A1 (en) *	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) *	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
RU2311930C2 (ru) *	2004-04-30	2007-12-10	Закрытое акционерное общество "ВЕРОФАРМ"	Пэгилированный интерферон для борьбы с вирусной инфекцией
AU2005260664A1 (en) *	2004-06-30	2006-01-12	Egen Corporation	Pegylated interferon alpha-1b
WO2007012059A2 (en) *	2005-07-19	2007-01-25	Nektar Therapeutics Al, Corporation	Method for preparing polymer maleimides
WO2007149594A2 (en) *	2006-06-23	2007-12-27	Quintessence Biosciences, Inc.	Modified ribonucleases
CN101491682A (zh) *	2008-04-30	2009-07-29	北京凯正生物工程发展有限责任公司	聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101591387A (zh) *	2008-05-28	2009-12-02	中国人民解放军军事医学科学院微生物流行病研究所	聚乙二醇化重组人干扰素ω偶合物
CN101514229B (zh) *	2009-04-03	2012-05-09	海南四环心脑血管药物研究院有限公司	人干扰素α衍生物及其聚乙二醇化修饰物

2010
- 2010-07-20 RU RU2010129824/10A patent/RU2447083C1/ru active
- 2010-09-24 SG SG2013003801A patent/SG187117A1/en unknown
- 2010-09-24 PH PH1/2012/502425A patent/PH12012502425A1/en unknown
- 2010-09-24 CU CUP2013000013A patent/CU24193B1/es active IP Right Grant
- 2010-09-24 KR KR1020137001858A patent/KR101586372B1/ko not_active Expired - Fee Related
- 2010-09-24 MY MYPI2013000216A patent/MY168784A/en unknown
- 2010-09-24 WO PCT/RU2010/000529 patent/WO2012011836A1/en not_active Ceased
- 2010-09-24 PE PE2013000084A patent/PE20131034A1/es not_active Application Discontinuation
- 2010-12-15 UA UAA201015114A patent/UA99766C2/uk unknown
2011
- 2011-04-01 BR BRPI1101565-9A patent/BRPI1101565A2/pt not_active IP Right Cessation
- 2011-06-21 EA EA201100809A patent/EA020257B1/ru not_active IP Right Cessation
- 2011-07-12 MX MX2011007458A patent/MX2011007458A/es active IP Right Grant
- 2011-07-19 CN CN201110214149.6A patent/CN102617736B/zh not_active Expired - Fee Related
- 2011-07-19 AR ARP110102606A patent/AR087227A1/es unknown
- 2011-07-20 UY UY0001033525A patent/UY33525A/es unknown
2013
- 2013-01-04 DO DO2013000002A patent/DOP2013000002A/es unknown
- 2013-01-18 EC ECSP13012398 patent/ECSP13012398A/es unknown
- 2013-01-18 CO CO13009157A patent/CO6680611A2/es unknown
- 2013-01-18 NI NI201300008A patent/NI201300008A/es unknown
- 2013-01-18 CR CR20130021A patent/CR20130021A/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5951974A (en) *	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
WO2004022630A2 (en) *	2002-09-09	2004-03-18	Nektar Therapeutics Al, Corporation	Water-soluble polymer alkanals

Also Published As

Publication number	Publication date
AR087227A1 (es)	2014-03-12
PH12012502425A1 (en)	2013-07-08
RU2447083C1 (ru)	2012-04-10
MX2011007458A (es)	2012-01-19
UA99766C2 (uk)	2012-09-25
HK1170504A1 (zh)	2013-03-01
KR20130056885A (ko)	2013-05-30
PE20131034A1 (es)	2013-09-27
BRPI1101565A2 (pt)	2012-12-04
CU20130013A7 (es)	2013-04-19
RU2010129824A (ru)	2012-01-27
CR20130021A (es)	2013-02-20
KR101586372B1 (ko)	2016-01-18
CU24193B1 (es)	2016-09-30
SG187117A1 (en)	2013-02-28
CN102617736B (zh)	2015-11-25
DOP2013000002A (es)	2013-09-15
MY168784A (en)	2018-12-04
UY33525A (es)	2012-02-29
CN102617736A (zh)	2012-08-01
ECSP13012398A (es)	2013-05-31
WO2012011836A1 (en)	2012-01-26
EA201100809A1 (ru)	2012-01-30
NI201300008A (es)	2014-05-26
CO6680611A2 (es)	2013-05-31

Publication	Publication Date	Title
EA020257B1 (ru)	2014-09-30	НОВЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
RU2446173C1 (ru)	2012-03-27	Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
ES2418833T3 (es)	2013-08-16	Formulaciones líquidas de interferón estabilizadas
EA009995B1 (ru)	2008-06-30	Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
EP2422770A1 (en)	2012-02-29	Formulations of peg-interferon alpha conjugates
EP1734988A2 (en)	2006-12-27	Interferon-beta polymer conjugates
US10881739B2 (en)	2021-01-05	Interleukin-11 PEGylation reaction intermediate composition
JP5363987B2 (ja)	2013-12-11	ポリエチレングリコール−ｇ−ｃｓｆ結合体
RU2576372C2 (ru)	2016-02-27	МОЛЕКУЛА ИНТЕРФЕРОНА-β-1а ЧЕЛОВЕКА, МОДИФИЦИРОВАННАЯ ПОЛИЭТИЛЕНГЛИКОЛЕМ, ОБЛАДАЮЩАЯ ПРОТИВОВИРУСНОЙ, ИММУНОМОДУЛИРУЮЩЕЙ И АНТИПРОЛИФЕРАТИВНОЙ АКТИВНОСТЯМИ, С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ, УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, УЛУЧШЕННЫМИ ФАРМАКОКИНЕТИЧЕСКИМИ И ФАРМАКОДИНАМИЧЕСКИМИ ПАРАМЕТРАМИ, ПРИГОДНАЯ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ
WO2017078571A1 (ru)	2017-05-11	Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
HK1170504B (en)	2016-12-09	The stable polyethylene glycol conjugate of interferon alpha, represented by one positional isomer
US20150329601A1 (en)	2015-11-19	Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof
HK1102563B (en)	2011-08-05	Stabilized interferon liquid formulations
HK1168757A (en)	2013-01-11	Formulations of peg-interferon alpha conjugates
EA021643B1 (ru)	2015-07-30	Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA022617B1 (ru)	2016-02-29	Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа

Legal Events

Date	Code	Title	Description
2020-02-29	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU